Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis.

Maekawa T, Abe T, Hajishengallis E, Hosur KB, DeAngelis RA, Ricklin D, Lambris JD, Hajishengallis G.

J Immunol. 2014 Jun 15;192(12):6020-7. doi: 10.4049/jimmunol.1400569. Epub 2014 May 7.

2.

Complement Involvement in Periodontitis: Molecular Mechanisms and Rational Therapeutic Approaches.

Hajishengallis G, Maekawa T, Abe T, Hajishengallis E, Lambris JD.

Adv Exp Med Biol. 2015;865:57-74. doi: 10.1007/978-3-319-18603-0_4. Review.

3.

Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3.

Maekawa T, Briones RA, Resuello RR, Tuplano JV, Hajishengallis E, Kajikawa T, Koutsogiannaki S, Garcia CA, Ricklin D, Lambris JD, Hajishengallis G.

J Clin Periodontol. 2016 Mar;43(3):238-49. doi: 10.1111/jcpe.12507. Epub 2016 Mar 3.

4.

Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist.

Abe T, Hosur KB, Hajishengallis E, Reis ES, Ricklin D, Lambris JD, Hajishengallis G.

J Immunol. 2012 Dec 1;189(11):5442-8. doi: 10.4049/jimmunol.1202339. Epub 2012 Oct 22.

5.

Human β-defensin 3 inhibits periodontitis development by suppressing inflammatory responses in macrophages.

Cui D, Lyu J, Li H, Lei L, Bian T, Li L, Yan F.

Mol Immunol. 2017 Nov;91:65-74. doi: 10.1016/j.molimm.2017.08.012. Epub 2017 Sep 5.

6.
7.

Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.

Hajishengallis G, Hajishengallis E, Kajikawa T, Wang B, Yancopoulou D, Ricklin D, Lambris JD.

Semin Immunol. 2016 Jun;28(3):285-91. doi: 10.1016/j.smim.2016.03.006. Epub 2016 Mar 24. Review.

8.

Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis.

Zhu Z, Chen W, Hao L, Zhu G, Lu Y, Li S, Wang L, Li YP.

J Clin Periodontol. 2015 Jul;42(7):599-608. doi: 10.1111/jcpe.12415. Epub 2015 Jun 11.

9.

Tamibarotene modulates the local immune response in experimental periodontitis.

Jin Y, Wang L, Liu D, Lin X.

Int Immunopharmacol. 2014 Dec;23(2):537-45. doi: 10.1016/j.intimp.2014.10.003. Epub 2014 Oct 14.

PMID:
25448496
10.

Regulation of osteoclast homeostasis and inflammatory bone loss by MFG-E8.

Abe T, Shin J, Hosur K, Udey MC, Chavakis T, Hajishengallis G.

J Immunol. 2014 Aug 1;193(3):1383-91. doi: 10.4049/jimmunol.1400970. Epub 2014 Jun 23.

11.

IL-33 Exacerbates Periodontal Disease through Induction of RANKL.

Malcolm J, Awang RA, Oliver-Bell J, Butcher JP, Campbell L, Adrados Planell A, Lappin DF, Fukada SY, Nile CJ, Liew FY, Culshaw S.

J Dent Res. 2015 Jul;94(7):968-75. doi: 10.1177/0022034515577815. Epub 2015 Mar 25.

PMID:
25808546
12.

Topical H2 antagonist prevents periodontitis in a rabbit model.

Hasturk H, Kantarci A, Ebrahimi N, Andry C, Holick M, Jones VL, Van Dyke TE.

Infect Immun. 2006 Apr;74(4):2402-14.

13.

The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss.

Liang S, Krauss JL, Domon H, McIntosh ML, Hosur KB, Qu H, Li F, Tzekou A, Lambris JD, Hajishengallis G.

J Immunol. 2011 Jan 15;186(2):869-77. doi: 10.4049/jimmunol.1003252. Epub 2010 Dec 13.

14.

Toll-Like Receptor 9-Mediated Inflammation Triggers Alveolar Bone Loss in Experimental Murine Periodontitis.

Kim PD, Xia-Juan X, Crump KE, Abe T, Hajishengallis G, Sahingur SE.

Infect Immun. 2015 Jul;83(7):2992-3002. doi: 10.1128/IAI.00424-15. Epub 2015 May 11.

15.

Porphyromonas gingivalis exacerbates ligature-induced, RANKL-dependent alveolar bone resorption via differential regulation of Toll-like receptor 2 (TLR2) and TLR4.

Lin J, Bi L, Yu X, Kawai T, Taubman MA, Shen B, Han X.

Infect Immun. 2014 Oct;82(10):4127-34. doi: 10.1128/IAI.02084-14. Epub 2014 Jul 21.

16.

Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement.

Hajishengallis G, Liang S, Payne MA, Hashim A, Jotwani R, Eskan MA, McIntosh ML, Alsam A, Kirkwood KL, Lambris JD, Darveau RP, Curtis MA.

Cell Host Microbe. 2011 Nov 17;10(5):497-506. doi: 10.1016/j.chom.2011.10.006. Epub 2011 Oct 27.

17.

Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis.

Kuula H, Salo T, Pirilä E, Tuomainen AM, Jauhiainen M, Uitto VJ, Tjäderhane L, Pussinen PJ, Sorsa T.

Infect Immun. 2009 Feb;77(2):850-9. doi: 10.1128/IAI.00873-08. Epub 2008 Nov 24.

18.

Immunization enhances inflammation and tissue destruction in response to Porphyromonas gingivalis.

Leone CW, Bokhadhoor H, Kuo D, Desta T, Yang J, Siqueira MF, Amar S, Graves DT.

Infect Immun. 2006 Apr;74(4):2286-92.

19.

Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of Marfan syndrome.

Suda N, Moriyama K, Ganburged G.

Infect Immun. 2013 Jan;81(1):182-8. doi: 10.1128/IAI.00886-12. Epub 2012 Oct 31.

20.

Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.

Hao L, Chen J, Zhu Z, Reddy MS, Mountz JD, Chen W, Li YP.

J Periodontol. 2015 Aug;86(8):972-83. doi: 10.1902/jop.2015.140643. Epub 2015 Apr 16.

Supplemental Content

Support Center